FDC Ltd

FDC Ltd., the Mumbai-based pharmaceutical company specialising in formulations and active pharmaceutical ingredients, delivered a disappointing Q3 FY26 performance, with net profit declining 23.60% year-on-year to ₹28.30 crores despite relatively flat revenue growth. The stock has plunged 28.90% from its 52-week high of ₹528.30, currently trading at ₹375.60 with a market capitalisation of ₹6,202 crores, reflecting mounting investor concerns over deteriorating operational efficiency and margin compression.

FDC Ltd’s valuation metrics have shifted notably, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving into the expensive territory compared to historical averages and peer benchmarks. This re-rating, coupled with a recent downgrade to a Strong Sell rating by MarketsMOJO, underscores growing concerns about the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 February 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 January 2026, providing investors with the latest insights into the company’s performance and outlook.

FDC Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with multiple indicators signalling a bearish trend. The company’s current market performance, combined with deteriorating technical parameters, has led to a downgrade in its Mojo Grade to Strong Sell, reflecting growing investor caution amid challenging market conditions.

FDC Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum as it transitions from a bearish to a mildly bearish trend. Despite a recent day gain of 3.16%, the company’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the evolving technical landscape of FDC Ltd, contextualising its price movements against broader market trends and sectoral performance.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 30 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a 3.62% gain on the day, the stock’s overall trend remains cautious amid mixed signals from MACD, RSI, and moving averages, underscoring the challenges facing investors in the Pharmaceuticals & Biotechnology sector.

FDC, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting recent shifts in its financial and technical outlook. The changes stem from a combination of valuation concerns, subdued financial performance, and technical indicators that suggest caution for investors.

FDC, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting shifts in its financial and technical outlook. This adjustment comes amid a backdrop of subdued operational performance and valuation concerns, prompting investors to reassess the stock’s position within its sector.

FDC, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, reflecting a change in price momentum and market sentiment. Recent data reveals a transition from mildly bearish to bearish technical trends, with several indicators signalling adjustments in the stock’s evaluation.

FDC, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical event where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend, indicating potential long-term weakness and trend deterioration for the stock.